Meclizine: Nursing Drug Guide, Sedation & Fall Risk / NCLEX Review

Meclizine hydrochloride (HCl) is an H₁-receptor antagonist with antiemetic and vestibular suppressant effects. U.S. products include prescription tablets for vertigo and OTC chewable tablets for motion sickness. Institutional protocols and product formulations may vary.

• Prescription brands/generics: Antivert and generic meclizine (commonly 12.5 mg and 25 mg tablets; some labels include 50 mg)
• OTC motion sickness: Bonine, Dramamine Less Drowsy, and store-brand motion-sickness relief chewable 25 mg tablets
• Formulations: Standard tablets (swallow whole per Rx labeling) and chewable tablets (must be chewed or crushed before swallowing; do not swallow chewable tablets whole)
• Not the same drug: Original Dramamine (dimenhydrinate) and other sedating antihistamines such as diphenhydramine — verify active ingredient during medication reconciliation

Per current U.S. prescribing and OTC labeling:

• Prescription (adults): Treatment of vertigo associated with diseases affecting the vestibular system (e.g., Ménière disease and other vestibular disorders per prescriber assessment)
• OTC: Prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness
• Hospital nursing use: Symptomatic vestibular suppression when ordered; distinguish expected symptom relief from new neurologic decline requiring escalation

Meclizine suppresses vestibular symptoms—it does not treat the underlying cause of acute stroke, hemorrhage, or other central neurologic emergency. Escalate new focal deficits or sudden severe headache per protocol.

The precise mechanism is unknown but is presumed to involve antagonism of the histamine H₁ receptor per prescribing information. Meclizine depresses labyrinth excitability and conduction in vestibular pathways, reducing motion-triggered nausea and vertigo sensation.

Because meclizine has CNS effects, nurses should expect drowsiness, possible anticholinergic symptoms (dry mouth, urinary hesitancy), and additive sedation with other CNS depressants—even when patients describe it as “less drowsy” than other antihistamines.

Match indication, formulation, and 24-hour total to the order and product label. Do not combine prescription vertigo dosing with OTC motion-sickness products without prescriber/pharmacy review.

Vertigo — prescription tablet labeling (adults)

Motion sickness — U.S. OTC chewable labeling (12 years and older)

↔On a small screen, swipe or scroll sideways to see the full table.

Renal / hepatic impairment

Missed dose: Not specified in the reviewed prescribing information. If a vertigo dose is missed, give when remembered per prescriber/pharmacy guidance unless near the next scheduled dose. For motion sickness, OTC labeling emphasizes pre-travel dosing one hour before travel.

• Absorption: Oral absorption with median T_max about 3 hours (range 1.5 to 6 h) for tablet dosage form per labeling
• Half-life: Plasma elimination half-life about 5 to 6 hours in humans
• Metabolism: CYP2D6 is the dominant enzyme; genetic polymorphism may contribute to inter-individual variability
• Distribution/elimination details: Human distribution characteristics not fully described in reviewed labeling

Answer these before the first dose or when reconciling home supply:

• Correct patient, drug, strength (12.5 mg vs 25 mg), formulation (tablet vs chewable), route, and time
• Only one sedating vestibular/antiemetic agent unless prescriber documents otherwise — check for duplicate meclizine, diphenhydramine, or promethazine on MAR and home list
• Home OTC motion-sickness chewables or travel packs on the MAR/home list
• 24-hour total within ordered or labeled maximum (Rx max 100 mg/day; OTC often 1–2 tablets once daily)
• Recent alcohol, opioids, benzodiazepines, or other CNS depressants on the MAR or home list
• Older adult: baseline cognition, fall risk, last void, orthostatic symptoms
• History of asthma, glaucoma, or prostate enlargement per warnings
• Pregnancy or breastfeeding — discuss risks/benefits with prescriber; human lactation data limited

• Hypersensitivity to meclizine or any inactive ingredient in the specific product

No additional absolute contraindications are listed in the reviewed prescription labeling beyond hypersensitivity. Use with caution in asthma, glaucoma, and enlargement of the prostate gland because of potential anticholinergic action.

↔On a small screen, swipe or scroll sideways to see the full table.

Standard tablets (prescription)

• Swallow whole — do not crush unless pharmacy approves alternate administration for a scored tablet
• Give with or without food per institutional practice unless patient reports GI upset
• Verify color, strength, and debossing (e.g., 12.5 mg blue vs 25 mg yellow on some generics)

Chewable tablets (OTC motion sickness)

• Chew or crush completely before swallowing — do not swallow chewable tablets whole
• OTC motion-sickness labeling: take one hour before travel starts
• Once-daily OTC dosing differs from divided prescription vertigo regimens — do not assume the same schedule

• Reduced intensity of vertigo or motion-triggered nausea within several hours of an oral dose (T_max median ~3 h)
• Improved ability to tolerate head movement, ambulation, or travel when motion-sickness prophylaxis timed correctly
• Decreased associated autonomic symptoms (nausea, vomiting) without excessive sedation at the lowest effective dose
• If vertigo persists at maximum labeled daily dose, contact prescriber rather than adding another sedating antiemetic

• Anaphylactic reaction — listed in labeling; stop drug and treat per emergency pathway (urticaria with angioedema, bronchospasm, hypotension)
• Acute altered mental status, inability to arouse, or new confusion — especially with CNS depressant stacking
• New focal neurologic deficits, sudden severe headache, or vertigo unlike baseline — may indicate stroke or other emergency, not expected drug effect
• Urinary retention, suprapubic discomfort, or inability to void with anticholinergic symptoms
• Significant hypotension, near-syncope, or fall after dose — assess orthostatics and sedation
• Rare blurred vision reported — assess safety for ambulation and driving; notify prescriber if persistent

Labeling identifies the following adverse reactions. Nursing priorities are sedation, CNS depression with co-medications, and anticholinergic symptoms.

↔On a small screen, swipe or scroll sideways to see the full table.

Specific overdose signs, treatment protocols, and toxicity thresholds are not specified in the reviewed prescribing information. Antihistamine overdose may present with exaggerated CNS depression and anticholinergic effects.

Antidote

No specific antidote is listed in the reviewed prescribing information. Management is expected to be symptomatic and supportive per toxicology guidance.

• Meclizine vs cyclizine — different drugs; verify spelling and active ingredient
• Meclizine vs dimenhydrinate (Dramamine original) — both used for motion sickness; do not double-dose
• Antivert vs Bonine vs Dramamine Less Drowsy — all may contain meclizine; reconcile home bottles
• 12.5 mg vs 25 mg vs 50 mg — color and debossing differ by manufacturer; tall-man labeling where available
• Chewable vs swallow-whole tablet — administration error if formulation ignored
• Meclizine vs diphenhydramine vs promethazine — all sedating; avoid stacking without review

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Level of sedation, orientation, and safe ability to ambulate
• Vertigo/nausea severity trend — is the vestibular symptom improving on current dose?
• Voiding pattern and urinary retention symptoms
• Orthostatic blood pressure and heart rate in older adults
• Signs of anaphylaxis or new neurologic deficits

Document

• Dose, strength, formulation (chewable vs tablet), time, and 24-hour cumulative total
• Home OTC motion-sickness reconciliation
• Sedation/fall assessment and prescriber/pharmacy notification when hold criteria met
• Patient teaching on driving restrictions and pre-travel dosing when discharged on OTC product

• Drowsiness may occur — avoid driving or operating dangerous machinery if sleepy; avoid alcohol and sedating medicines unless approved
• For motion sickness: take dose one hour before travel starts; chew chewable tablets completely before swallowing
• Do not combine prescription meclizine with OTC motion-sickness products without checking with the care team
• Report throat swelling, trouble breathing, widespread rash, inability to urinate, severe confusion, or falls
• Read active ingredients on travel/motion-sickness products — many contain meclizine under store brand names
• Pregnant or breastfeeding — discuss with prescriber before use

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for meclizine using a tabbed case (MAR, labs, history, nursing notes), then priority action, select-all-that-apply cues, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise sedation and duplicate OTC dosing → analyse fall and CNS-stacking risk → prioritise → act → evaluate outcomes after de-escalation.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.